NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,049.00
- Market cap
- ₹50,312 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.6×Sector 46.1×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Management Change
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Gland Pharma Acquisition Worth ₹199.5 Cr
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
- Value
- ₹199.5 Cr
- Execution
- By October 31, 2026
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd. sold 98,97,000 shares of Gland Pharma Ltd via open market transactions. This reduced their stake from 51.76% to 45.76%.
- Promoter stake change
- -6.00%
Other business update announcements
All →OnMobile Global Business Update
OnMobile Global Limited executed a distribution agreement with Savex Technologies Private Limited for its ONMO+ Smart Console in India. The counterparty is unrelated and no shares were issued, so no value is disclosed.
OnEMI Technology Solutions Business Update
OnEMI Technology Solutions (Kissht) disclosed its Key Performance Indicators for the quarter ended 30 September 2026. The KPIs, including those defined in its May 2026 prospectus, are published on the company website.
Hero MotoCorp Business Update
Hero MotoCorp updated its code of practices for fair disclosure of unpublished price-sensitive information, effective 28 October 2026. The revised code governs disclosure, spokespersons and analyst interactions.
Cybele Industries Business Update
Cybele Industries disclosed joint venture discussions with a third party, still at an initial stage. No agreement has been executed and no value is stated.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Vascon Engineers Business Update
Vascon Engineers awarded Neobridge Realty LLP a Rs.72 Crore shell and core work contract over 25 months. The contract is excluding GST and is described as ordinary course of business.
- Value
- ₹72.00 Cr
- Execution
- 25 months